Teva To Sue FDA Over Pravachol Marketing Exclusivity

Law360 (July 6, 2005, 12:00 AM EDT) -- Israeli drug maker Teva Pharmaceutical Industries Ltd. said Wednesday it would sue the U.S. Food and Drug Administration over a decision that effectively wiped out the company’s marketing exclusivity for a generic version of Bristol-Myers Squibb Co.'s cholesterol medication Pravachol.

Teva said it strongly disagreed with the FDA ruling, which determined that the 180-day exclusivity period for generic versions Pravachol began on August 22, when another generic drug maker's lawsuit against Bristol-Myers was dismissed.

In that case, Canadian drug maker Apotex Inc. had sought a declaratory...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.